Publication:
Combination of second-generation proteasome inhibitor carfilzomib with bortezomib in four different breast cancer cell lin

Simple item page
dc.contributor.authorYILMAZ GÖLER, AYŞE MİNE
dc.contributor.authorŞAHİN, ALİ
dc.contributor.authorYILMAZ, BETÜL
dc.contributor.authorsAltundag E. M., Yilmaz A. M., Sahin A., Yilmaz B.
dc.date.accessioned2023-04-03T10:26:49Z
dc.date.available2023-04-03T10:26:49Z
dc.date.issued2022-01-01
dc.description.abstractBackground: Proteasome inhibitors target different pathways in cells and therefore are promising drugs in cancer therapy. The use of these inhibitors is approved mainly in hematological cancers, and recently many clinical trials and preclinical studies have been conducted on efficacy in solid tumors. Carfilzomib is a second-generation inhibitor and was developed to decrease the side effects of bortezomib. Although there are many valid therapies for breast cancer, resistance and recurrence are inevitable in many cases and the proteasomal system plays an important role in related pathways. Objective: This study is a preliminary work to evaluate the combined effects of bortezomib and carfilzomib in four different breast cancer cells. Methods: MDA-MB-231, MCF-7, UACC-2087, and SKBR-3 cell lines were used. Cell viability was determined using bortezomib and carfilzomib alone and in combination. Combination effect values were determined using the Chou-Talalay method. Apoptosis, proteasome activity, cleaved PARP, and HSP70 expressions were analyzed in the determined doses. Results: The response to the combination of the two inhibitors was different in four cell lines. Apoptosis was significantly higher in combination groups compared to carfilzomib in three cell lines except for SKBR-3, and higher in the combination group compared to bortezomib only in UACC-2087. Combination decreased cleaved PARP levels in MDA-MB-231 and MCF-7 and increased SKBR-3 compared to bortezomib. HSP70 levels decreased in combination with UACC-2087 and SKBR-3 compared to carfilzomib. Conclusion: Taken together, the combination of the two inhibitors was more apoptotic compared to carfilzomib and apoptosis was higher only in UACC-2087 compared to bortezomib. This apoptosis data can not be directly correlated to the degree of proteasome inhibition, PARP cleavage, and HSP70 response.
dc.identifier.citationAltundag E. M., Yilmaz A. M., Sahin A., Yilmaz B., "Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines", ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, cilt.22, sa.16, ss.2909-2918, 2022
dc.identifier.doi10.2174/1871520622666220329175501
dc.identifier.endpage2918
dc.identifier.issn1871-5206
dc.identifier.issue16
dc.identifier.startpage2909
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/35352669/
dc.identifier.urihttps://hdl.handle.net/11424/288095
dc.identifier.volume22
dc.language.isoeng
dc.relation.ispartofANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTıp
dc.subjectTemel Eczacılık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectKimya
dc.subjectBiyokimya
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectMedicine
dc.subjectBasic Pharmaceutics Sciences
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectPharmacology and Therapeutics
dc.subjectLife Sciences
dc.subjectChemistry
dc.subjectBiochemistry
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectKİMYA, TIBBİ
dc.subjectTemel Bilimler (SCI)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectONCOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectCHEMISTRY, MEDICINAL
dc.subjectCHEMISTRY
dc.subjectNatural Sciences (SCI)
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectLife Sciences (LIFE)
dc.subjectFarmakoloji
dc.subjectFarmakoloji, Toksikoloji ve Eczacılık (çeşitli)
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectFarmakoloji (tıbbi)
dc.subjectİlaç Rehberleri
dc.subjectKimya (çeşitli)
dc.subjectGenel Kimya
dc.subjectFizik Bilimleri
dc.subjectPharmacy
dc.subjectPharmacology
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology (medical)
dc.subjectDrug Guides
dc.subjectChemistry (miscellaneous)
dc.subjectGeneral Chemistry
dc.subjectPhysical Sciences
dc.subjectBreast cancer cells
dc.subjectbortezomib
dc.subjectcarfilzomib
dc.subjectcell lines
dc.subjectPARP levels
dc.subjectHSP70
dc.subjectTHERAPEUTIC TARGET
dc.subjectEXPRESSION
dc.subjectACTIVATION
dc.subjectPATHWAY
dc.subjectPROTECTS
dc.subjectMYELOMA
dc.titleCombination of second-generation proteasome inhibitor carfilzomib with bortezomib in four different breast cancer cell lin
dc.typearticle
dspace.entity.typePublication
local.avesis.idd2424ade-802f-4de1-a2fa-81fa51867f46
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication8a72311b-9078-47c0-9fd8-bd73292b7739
relation.isAuthorOfPublicationdda71138-8ce4-4265-89b2-73bc94786a4f
relation.isAuthorOfPublication81633a07-e5fb-4760-b3ef-bf0878d87827
relation.isAuthorOfPublication.latestForDiscovery8a72311b-9078-47c0-9fd8-bd73292b7739

Files

Collections

Research Outputs